Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.83) by 4.82 percent. This is a 11.24 percent increase over losses of $(0.89) per share from the same period last year.
Lumos Pharma Q4 EPS $(0.98) Misses $(0.93) Estimate, Sales $512.00K Beat $110.00K Estimate
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.93) by 5.38 percent. This is a 44.12 percent decrease over losses of $(0.68) per share from the
